Ferric Ammonium Citrate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1185-57-5
Molecular formula
C6H11FeNO7+3
Molecular weight
265 g/mol
Drug class
Ferric ammonium citrate complexoral iron source and nutritional iron supplement
Mechanism of action
Provides ferric iron that is reduced and absorbed through intestinal iron-uptake pathways, then incorporated into transferrin, haemoglobin and iron stores. Citrate and ammonium are complexing/counter-ion components.
Indications / reported uses
Treatment or prevention of iron deficiency and iron-deficiency anaemia in authorised oral iron preparations; indications and elemental iron dose depend on the formulation and product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ferric Ammonium Citrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ferric Ammonium Citrate Permitted Daily Exposure (PDE) report (the Ferric Ammonium Citrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ferric Ammonium Citrate Occupational Exposure Limit (OEL) report (the Ferric Ammonium Citrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.